Does the media favor ALLO or CRSP?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 4 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Allogene Therapeutics' score of 0.53 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or AXSM?

In the previous week, Axsome Therapeutics had 3 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Axsome Therapeutics' score of 0.67 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to CRSP or BEAM?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 4 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Beam Therapeutics' score of 0.71 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EDIT or CRSP?

In the previous week, Editas Medicine had 29 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 35 mentions for Editas Medicine and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Editas Medicine's score of 0.75 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KALA or CRSP more profitable?

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% CRISPR Therapeutics -13,856.54% -25.66% -20.39%

Does the media prefer KALA or CRSP?

In the previous week, CRISPR Therapeutics had 3 more articles in the media than KALA BIO. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 3 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 1.33 beat KALA BIO's score of 0.88 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CRISPR Therapeutics (CRSP) Competitors

$56.10 -0.28 (-0.50%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$55.65 -0.45 (-0.80%)

As of 05/29/2026 07:58 PM Eastern

Compare

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you buy CRISPR Therapeutics stock or one of its competitors? MarketBeat compares CRISPR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Allogene Therapeutics presently has a consensus price target of $8.52, suggesting a potential upside of 292.73%. CRISPR Therapeutics has a consensus price target of $65.47, suggesting a potential upside of 16.71%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 4 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Allogene Therapeutics' score of 0.53 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

Allogene Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	37,448.78	-$190.89M	-$0.77	N/A
CRISPR Therapeutics	$3.51M	1,541.44	-$581.60M	-$6.22	N/A

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,541.44	-$581.60M	-$6.22	N/A
Axsome Therapeutics	$638.50M	18.90	-$183.17M	-$3.73	N/A

CRISPR Therapeutics presently has a consensus target price of $65.47, indicating a potential upside of 16.71%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 7.16%. Given CRISPR Therapeutics' higher probable upside, equities analysts clearly believe CRISPR Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Axsome Therapeutics had 3 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Axsome Therapeutics' score of 0.67 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Axsome Therapeutics has a net margin of -26.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,541.44	-$581.60M	-$6.22	N/A
Beam Therapeutics	$139.74M	24.24	-$79.99M	-$0.68	N/A

CRISPR Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 4 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Beam Therapeutics' score of 0.71 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Beam Therapeutics has a net margin of -39.66% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

CRISPR Therapeutics currently has a consensus target price of $65.47, indicating a potential upside of 16.71%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 42.22%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

CRISPR Therapeutics and Beam Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	8.36	-$160.06M	-$1.23	N/A
CRISPR Therapeutics	$3.51M	1,541.44	-$581.60M	-$6.22	N/A

Editas Medicine presently has a consensus target price of $5.40, indicating a potential upside of 56.07%. CRISPR Therapeutics has a consensus target price of $65.47, indicating a potential upside of 16.71%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53

Editas Medicine has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Editas Medicine had 29 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 35 mentions for Editas Medicine and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Editas Medicine's score of 0.75 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Summary

Editas Medicine beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

KALA BIO has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
CRISPR Therapeutics	$3.51M	1,541.44	-$581.60M	-$6.22	N/A

KALA BIO has a beta of -2.4, indicating that its stock price is 340% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

KALA BIO currently has a consensus price target of $1,018.75, suggesting a potential upside of 45,583.86%. CRISPR Therapeutics has a consensus price target of $65.47, suggesting a potential upside of 16.71%. Given KALA BIO's higher probable upside, research analysts clearly believe KALA BIO is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53

In the previous week, CRISPR Therapeutics had 3 more articles in the media than KALA BIO. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 3 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 1.33 beat KALA BIO's score of 0.88 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

CRISPR Therapeutics beats KALA BIO on 12 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRSP vs. The Competition

Export

Metric	CRISPR Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.42B	$3.41B	$6.58B	$12.59B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	-9.02	10.39	18.22	23.45
Price / Sales	1,541.44	334.85	561.77	114.93
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	2.78	6.93	10.04	6.86
Net Income	-$581.60M	$24.20M	$3.56B	$337.26M
7 Day Performance	11.39%	4.11%	2.85%	3.58%
1 Month Performance	7.18%	6.66%	4.59%	5.71%
1 Year Performance	55.65%	66.00%	37.62%	39.70%

CRISPR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRSP CRISPR Therapeutics	2.4549 of 5 stars	$56.10 -0.5%	$65.47 +16.7%	+55.6%	$5.42B	$3.51M	N/A	460	Positive News Analyst Forecast
ALLO Allogene Therapeutics	2.6295 of 5 stars	$1.94 -3.0%	$8.52 +339.3%	+86.3%	$474.95M	$20K	N/A	310	News Coverage
AXSM Axsome Therapeutics	2.4089 of 5 stars	$227.40 -0.1%	$251.26 +10.5%	+123.5%	$11.70B	$638.50M	N/A	380
BEAM Beam Therapeutics	2.307 of 5 stars	$26.81 -4.0%	$46.83 +74.7%	+109.2%	$2.76B	$139.74M	N/A	510
EDIT Editas Medicine	3.4014 of 5 stars	$2.53 -3.4%	$5.40 +113.4%	+99.4%	$247.71M	$40.52M	N/A	230	Trending News Analyst Forecast Options Volume Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Do institutionals and insiders have more ownership in ALLO or CRSP?

Do analysts prefer ALLO or CRSP?

Does the media favor ALLO or CRSP?

Is ALLO or CRSP more profitable?

Which has more volatility and risk, ALLO or CRSP?

Which has better valuation & earnings, ALLO or CRSP?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Do institutionals & insiders hold more shares of CRSP or AXSM?

Which has preferable valuation & earnings, CRSP or AXSM?

Do analysts rate CRSP or AXSM?

Does the media favor CRSP or AXSM?

Is CRSP or AXSM more profitable?

Which has more volatility & risk, CRSP or AXSM?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Which has higher earnings & valuation, CRSP or BEAM?

Which has more volatility & risk, CRSP or BEAM?

Does the media refer more to CRSP or BEAM?

Do insiders & institutionals hold more shares of CRSP or BEAM?

Is CRSP or BEAM more profitable?

Do analysts rate CRSP or BEAM?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Which has stronger valuation and earnings, EDIT or CRSP?

Do analysts rate EDIT or CRSP?

Which has more risk & volatility, EDIT or CRSP?

Do institutionals & insiders believe in EDIT or CRSP?

Does the media refer more to EDIT or CRSP?

Is EDIT or CRSP more profitable?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Is KALA or CRSP more profitable?

Which has preferable valuation & earnings, KALA or CRSP?

Which has more volatility and risk, KALA or CRSP?

Do analysts prefer KALA or CRSP?

Does the media prefer KALA or CRSP?

Do institutionals and insiders hold more shares of KALA or CRSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools